What made sesquiterpene lactones reach cancer clinical trials?

被引：512

作者：

Ghantous, Akram ^{[1
,2
]}

Gali-Muhtasib, Hala ^{[1
,2
]}

Vuorela, Heikki ^{[3
]}

Saliba, Najat A. ^{[2
,4
]}

Darwiche, Nadine ^{[1
,2
]}

机构：

[1] Amer Univ Beirut, Dept Biol, Beirut 11072020, Lebanon

[2] Amer Univ Beirut, Nat Conservat Ctr Sustainable Futures, Beirut 11072020, Lebanon

[3] Univ Helsinki, Fac Pharm, Div Pharmaceut Biol, FIN-00014 Helsinki, Finland

[4] Amer Univ Beirut, Dept Chem, Beirut 11072020, Lebanon

来源：

DRUG DISCOVERY TODAY | 2010年 / 15卷 / 15-16期

关键词：

NF-KAPPA-B; STRUCTURE-CYTOTOXICITY RELATIONSHIPS; MYELOGENOUS LEUKEMIA STEM; IN-VIVO ACTIVITY; ANTITUMOR AGENTS; ALPHA-METHYLENE; PROSTATE-CANCER; EXPRESSION PROFILES; MEDICINAL-PLANTS; TUMOR INHIBITORS;

D O I：

10.1016/j.drudis.2010.06.002

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Sesquiterpene lactones (SLs) are plant-derived compounds often used in traditional medicine against inflammation and cancer. This review focuses on the chemical and biological properties of SLs that lead to enhanced anticancer and anti-inflammatory effects. The chemical properties comprise alkylating center reactivity, lipophilicity, and molecular geometry and electronic features. SLs in clinical trials are artemisinin, thapsigargin and parthenolide and many of their synthetic derivatives. These drugs are selective toward tumor and cancer stem cells by targeting specific signaling pathways, which make them lead compounds in cancer clinical trials.

引用

页码：668 / 678

页数：11

共 50 条

[1] Perspectives on Sesquiterpene Lactones in Inflammation and Cancer
Merfort, Irmgard
[J]. CURRENT DRUG TARGETS, 2011, 12 (11) : 1560 - 1573
[2] Sesquiterpene lactones as potential agents against cancer
Estevez Sarmiento, Francisco
[J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2019, 125 : 18 - 18
[3] What is the future for cancer clinical trials?
Perrone, Francesco
[J]. FUTURE ONCOLOGY, 2015, 11 (01) : 5 - 7
[4] Role of sesquiterpene lactones against human ovarian cancer
Fadayomi, Idowu Eniafe
Forsyth, Nicholas
Li, Wen-Wu
[J]. BIOCHEMICAL PHARMACOLOGY, 2017, 139 : 134 - 135
[5] Sesquiterpene Lactones as Promising Candidates for Cancer Therapy: Focus on Pancreatic Cancer
Cecilia Laurella, Laura
Talin Mirakian, Nadia
Noe Garcia, Maria
Hector Grasso, Daniel
Patricia Sulsen, Valeria
Laura Papademetrio, Daniela
[J]. MOLECULES, 2022, 27 (11):
[6] What dominates the changeable pharmacokinetics of natural sesquiterpene lactones and diterpene lactones: a review focusing on absorption and metabolism
Yu, Ziwei
Chen, Ziqiang
Li, Qijuan
Yang, Ke
Huang, Zecheng
Wang, Wenjun
Zhao, Siyu
Hu, Huiling
[J]. DRUG METABOLISM REVIEWS, 2021, 53 (01) : 122 - 140
[7] Vernolide-A and Vernodaline: Sesquiterpene Lactones with Cytotoxicity against Cancer
Nguyen, Nguyen H.
Minh Tan Nguyen
Little, Peter J.
Anh Thu Do
Phuong Trinh Tran
Xuan Nam Vo
Bich Hang Do
[J]. JOURNAL OF ENVIRONMENTAL PATHOLOGY TOXICOLOGY AND ONCOLOGY, 2020, 39 (04) : 299 - 308
[8] Cytotoxic activity of sesquiterpene lactones on breast cancer stem cells
Wendy, S.
Rodrigo, V.
Atena, M.
Gloria, R.
Giovanna, A.
Olov, S.
Stina, O.
[J]. EUROPEAN JOURNAL OF CANCER, 2016, 69 : S116 - S117
[9] Sesquiterpene lactones as emerging biomolecules to cease cancer by targeting apoptosis
Hsu, Chou-Yi
Rajabi, Sadegh
Hamzeloo-Moghadam, Maryam
Kumar, Abhinav
Maresca, Marc
Ghildiyal, Pallavi
[J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
[10] Clinical trials in cancer: What makes for a successful study?
Tobias, JS
Baum, M
Thornton, H
[J]. ANNALS OF ONCOLOGY, 2000, 11 (11) : 1371 - 1373

← 1 2 3 4 5 →